Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

June 19, 2025 updated by: Orbus Therapeutics, Inc.

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose.

Duration of participation will be up to approximately 104 weeks in total per patient.

Screening Period - A maximum screening duration of 4 weeks.

Treatment Period - Up to approximately 104 weeks.

Follow-Up Visit - 4 weeks from last treatment.

Long-term Survival Follow-Up - up to 2 years from last treatment.

A total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the RP2D to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics).

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Withdrawn
        • University of Alabama at Birmingham
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Hospital
        • Principal Investigator:
          • Tobias Walbert, MD, PhD, MPH
        • Contact:
        • Contact:
    • New York
      • New York, New York, United States, 10032
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Recruiting
        • Duke University
        • Principal Investigator:
          • Annick Desjardins, MD, FRCPC
        • Contact:
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • The Cleveland Clinic
        • Principal Investigator:
          • David Peereboom, MD
        • Contact:
        • Contact:
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Recruiting
        • Brown University Health/Rhode Island Hospital
        • Principal Investigator:
          • Eric Wong, MD
        • Contact:
        • Contact:
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • UT MD Anderson Cancer Center
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlos Kamiya Matsuoka, MD
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Recruiting
        • University of Utah, Huntsman Cancer Institute
        • Principal Investigator:
          • Howard Colman, MD, PhD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021 tumor classification.
  • Completed external beam radiation therapy per standard of care.
  • Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated adjuvant TMZ treatment through at least 2 and not more than 4 cycles.
  • Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.
  • Willing to abstain from intercourse or use acceptable contraceptive methods.
  • If taking corticosteroids, must be on a stable or decreasing dose.

Exclusion Criteria:

  • Recent history of recurrent or metastatic cancer that could confound response assessments
  • Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).
  • Prior Optune treatment.
  • Active infection or serious intercurrent medical illness.
  • Poorly controlled seizures.
  • Significant cardiac disease within 6 months of enrollment.
  • Poorly controlled diabetes.
  • Use of another investigational agent within 30 days of enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Eflornithine Dose Level 1 + Temozolomide
Drug: Eflornithine (Dose Level 1)
Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
  • DFMO
Drug: Temozolomide
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
  • Temodar
  • TMZ
Experimental: Eflornithine Dose Level 2 + Temozolomide
Drug: Temozolomide
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
  • Temodar
  • TMZ
Drug: Eflornithine (Dose Level 2)
Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
  • DFMO
Experimental: Eflornithine Dose Level -1 + Temozolomide
Drug: Temozolomide
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Other Names:
  • Temodar
  • TMZ
Drug: Eflornithine (Dose Level -1)
Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Other Names:
  • DFMO

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of Dose Limiting Toxicities
Time Frame: 8 weeks
Protocol Defined Dose Limiting Toxicities
8 weeks
Incidence of TEAEs All Grades
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
All Grades
From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Grade 3+
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Grade 3+
From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Serious
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Serious
From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Leading to Discontinuation
Time Frame: From enrollment to the end of treatment
Leading to Discontinuation
From enrollment to the end of treatment
Vital Signs (Heart and Respiratory Rate)
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Change from Baseline in Heart Rate and Respiratory Rate
From enrollment to the follow-up visit 4 weeks after end of treatment
Vital Signs (Blood Pressure)
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Change from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Lab abnormalities by CTCAE v5.0 Grade
From enrollment to the follow-up visit 4 weeks after end of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pharmacokinetics Cmax
Time Frame: Baseline to Steady State (2 weeks)
observed maximum concentration
Baseline to Steady State (2 weeks)
Pharmacokinetics Cmin
Time Frame: Baseline to Steady State (2 weeks)
observed minimum concentration
Baseline to Steady State (2 weeks)
Pharmacokinetics Tmax
Time Frame: Baseline to Steady State (2 weeks)
time of observed maximum concentration
Baseline to Steady State (2 weeks)
Pharmacokinetics AUCt
Time Frame: Baseline to Steady State (2 weeks)
area under the concentration-time curve
Baseline to Steady State (2 weeks)
Pharmacokinetics lambdaz
Time Frame: Baseline to Steady State (2 weeks)
elimination rate constant
Baseline to Steady State (2 weeks)
Pharmacokinetics t 1/2
Time Frame: Baseline to Steady State (2 weeks)
elimination half life
Baseline to Steady State (2 weeks)
QTcF-Concentration Relationship
Time Frame: Baseline to Steady State (2 weeks)
Assessment of change in QTcF relative to plasma concentration of eflornithine
Baseline to Steady State (2 weeks)
Assessment of QTcF
Time Frame: Baseline to Steady State (2 weeks)
Change from baseline in QTcF
Baseline to Steady State (2 weeks)
Overall Survival
Time Frame: From enrollment to up to 2 years after last dose
Until death or initiation of new anticancer therapy
From enrollment to up to 2 years after last dose
Progression Free Survival
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Per RANO Criteria as assessed by MRI
From enrollment to the follow-up visit 4 weeks after end of treatment
Overall Response Rate
Time Frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Per RANO Criteria as assessed by MRI
From enrollment to the follow-up visit 4 weeks after end of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Orbus Therapeutics, Inc.

Investigators

  • Principal Investigator: Howard Colman, MD, PhD, Huntsman Cancer Institute/ University of Utah

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 24, 2023

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

May 3, 2023

First Submitted That Met QC Criteria

May 19, 2023

First Posted (Actual)

May 30, 2023

Study Record Updates

Last Update Posted (Estimated)

June 25, 2025

Last Update Submitted That Met QC Criteria

June 19, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OT-21-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioblastoma

Clinical Trials on Eflornithine (Dose Level 1)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe